Minerva Neurosciences Inc
$ 4.51
-2.38%
12 Jun - close price
- Market Cap 210,115,000 USD
- Current Price $ 4.51
- High / Low $ 4.75 / 4.40
- Stock P/E N/A
- Book Value -5.79
- EPS -37.03
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -6.75 %
- 52 Week High 8.80
- 52 Week Low 1.57
About
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products for the treatment of diseases of the central nervous system. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$9.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-11 | 2025-11-05 | 2025-08-14 | 2025-05-13 | 2025-02-25 | 2024-11-05 | 2024-08-06 | 2024-05-01 | 2024-02-22 | 2023-11-07 | 2023-08-01 |
| Reported EPS | -0.17 | -0.64 | -0.36 | -0.43 | -0.5 | -0.56 | 2.97 | -1.09 | -1.13 | -1.39 | -1.03 | -1.12 |
| Estimated EPS | -0.138 | -0.11 | -0.35 | -0.9 | -1.07 | -1.05 | -1.01 | -0.97 | -1.2 | -0.88 | -0.77 | -0.44 |
| Surprise | -0.032 | -0.53 | -0.01 | 0.47 | 0.57 | 0.49 | 3.98 | -0.12 | 0.07 | -0.51 | -0.26 | -0.68 |
| Surprise Percentage | -23.1884% | -481.8182% | -2.8571% | 52.2222% | 53.271% | 46.6667% | 394.0594% | -12.3711% | 5.8333% | -57.9545% | -33.7662% | -154.5455% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NERV
2026-06-08 07:09:11
Minerva Neurosciences (Nasdaq:NERV) is a clinical-stage biopharmaceutical company focused on central nervous system diseases, with its lead product candidate roluperidone in a Phase 3 confirmatory trial for negative symptoms of schizophrenia. The company faces significant risks including negative shareholder equity, unprofitability, substantial shareholder dilution, and volatile share prices, as highlighted by recent financial announcements and risk assessments. Despite these challenges, Minerva continues its clinical development and recently formed a Scientific Advisory Board to guide its R&D activities.
2026-06-06 05:09:53
Minerva Neurosciences' SVP, CFO, and Secretary, Frederick W. Ahlholm, was granted 680,000 employee stock options with an exercise price of $4.6800 per share, expiring on June 2, 2036. The options will vest 25% on June 3, 2027, with the remainder vesting in equal quarterly installments over three years. This transaction, a compensation-related award, did not involve any share sales or purchases by the CFO.
2026-06-05 21:40:19
Minerva Neurosciences (NERV) director Inderjit Kaul was granted 50,000 stock options as equity compensation. The options have an exercise price of $4.68 per share and vest in four equal quarterly installments, beginning three months after June 3, 2026. Following this grant, Kaul holds 50,000 options, with no reported open-market purchases or sales.
2026-06-05 21:40:18
Minerva Neurosciences director G Jan Van Heek was granted 50,000 stock options with an exercise price of $4.68 per share, expiring on June 2, 2036. The options will vest in four equal quarterly installments, contingent on his continued service as a non-employee director. This transaction is classified as an acquisition of derivative securities, not a purchase or sale of common shares.
2026-06-05 21:40:18
Minerva Neurosciences (NERV) has granted 50,000 stock options to director Hans Peter Hasler with an exercise price of $4.68 per share and an expiration date of June 2, 2036. The options will vest in four equal quarterly installments, contingent on his continued service as a non-employee director. This transaction is detailed in a recent SEC Form 4 filing.
2026-06-05 21:40:18
Minerva Neurosciences (NERV) has granted director Fouzia Laghrissi-Thode 50,000 stock options with an exercise price of $4.68 per share. The options expire on June 2, 2036, and vest in four equal quarterly installments, contingent on her continued service as a non-employee director. This grant is a compensation-related award and does not involve open-market stock transactions.
